When Abigail Johnston’s first child entered preschool six years ago, a vigilant pediatrician recommended an unusual strategy for minimizing germ exposure for the rest of the family. “Every day when my son came home,...
A new program specializes in concerns of gay and bisexual men with prostate cancer, and other cancer research news of the week.
All photos ©2021 AACR/Vera LaMarche/Whitney Thomas
Cancer is a very complex disease. Cancer cells often have the ability to rewire some of their functions to survive in harsh environmental conditions and bypass the toxic effect of therapies. But, paradoxically, some of the alterations...
The FDA approved an immune checkpoint inhibitor for patients with stage IIB or IIC melanoma following surgical removal of their tumor. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic pembrolizumab (Keytruda) for...
Some cancer centers scrutinized for lack of pricing transparency, and an imaging drug helps surgeons better identify ovarian cancer with fluorescent lighting.
The FDA approved a monoclonal antibody combined with chemotherapy TO TREAT certain childhood blood cancers that express the protein CD20. The U.S. Food and Drug Administration (FDA) has approved rituximab (Rituxan), in combination with...
As you snack on turkey sandwiches and leftover pumpkin pie, check out the articles highlighted by the editors of the 10 AACR journals for the month of November. This month, the selected articles include...
The U.S. FDA approved a new combination of existing drugs to treat certain patients with multiple myeloma The U.S. Food and Drug Administration (FDA) approved a new combination therapy for multiple myeloma in adult...
A new drug approved by the U.S. FDA may help surgeons find cancer more easily and reduce the likelihood of leaving cancer cells behind The U.S. Food and Drug Administration (FDA) approved the imaging...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More